In Brief: FTC, FDA Enforcement; Insider Trading On NBTY Sale; Comment Period On Label Changes

FTC says Pure Green Coffee perks false claims; NBTY shareholder settles insider trading case; scientific citations trigger warning letter; supplement labels must detail plant source; scientific citations trigger warning; and more news In Brief.

The Federal Trade Commission alleges NBP Advertising Inc.’s Pure Green Coffee business makes false claims about a self-named supplement and creates fake blogs and news sites to promote the weight loss product, according to a May 19 announcement. In addition, NBP misappropriated logos from actual news organizations, including CNN, to confuse consumers about whether they are viewing an advertisement or news piece, according to FTC’s complaint filed in the U.S. District Court for the Middle District of Florida, Tampa Division. The commission also notes the Tampa-based firm failed to disclose it paid endorsers for video testimonials and provided them free product. The allegations recall an enforcement blitz that FTC brought against at least 10 affiliate marketers of acai supplements in 2011 for faking news investigations to advertise their supplements Also see "FTC Continues Acai Crackdown With Blitz Against Affiliate Marketers" - Pink Sheet, 25 April, 2011..

A former [NBTY Inc.] board member and some of his family members agree to pay $500,000 to resolve allegations of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

US FTC Continues Effort To Eliminate Orange Book’s Improper Patent Listings

 

In a somewhat surprising move, President Trump’s Federal Trade Commission is continuing a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon discussed the impact of the move on the generic drug industry.

HHS Secretary Favors Regenerative Medicine Over Traditional Pharma: Blessing And Curse?

 

Cell and gene therapy developers may not have to contend with HHS Secretary Robert F. Kennedy Jr.’s animosity like the traditional pharma industry, but his disinterest in distinguishing between the good and bad actors in the space could backfire.

‘Clean Sweep’ Of US CDC Vaccine Committee Puts Kennedy In Driver’s Seat

 

With a 25-27 June meeting looming, HHS Secretary Robert F. Kennedy Jr. can fill all 17 spots on the CDC's Advisory Committee on Immunization Practices with people he says will "exercise independent judgment."

Generic Drug Office’s Policy Staff Returning To US FDA

 

The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.

More from North America

Elegy For SACHRP: US HHS Research Protection Panel Tackled Tough Pediatric Trial Questions

 

The termination of the HHS Secretary’s Committee on Human Research Protections closed an important forum for discussing pediatrics and pregnancy in clinical trial design, a former SACHRP chair said.

Payment Cap Not Always Solution For Unaffordable Drugs, Maryland PDAB Director Says

 
• By 

The state's Prescription Drug Affordability Board, the oldest of a growing list of the boards, chose six drugs for affordability reviews and has the authority to set a ceiling on the amount state and local government payers would reimburse for them.

Future Of US FDA’s Diversity Action Plan Guidance ‘Up In The Air’ As Statutory Deadline Looms

 
• By 

A 26 June deadline looms for the final guidance even though a draft guidance was removed from the agency’s website to comply with President Trump’s gender ideology executive order. The concepts underpinning the guidance are still relevant, legal experts say.